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Abstract 
BACKGROUND: Concomitant thymoma and T- lymphoblastic/leukaemia lymphoma is possible. Secondary 
thymoma after treatment for T-lymphoblastic/leukaemia lymphoma was also occasionally reported, although this 
is quite rare. 
CASE REPORT: We report a case of 44-year-old women with secondary thymoma after chemotherapy treatment 
for T Acute Lymphoblastic leukaemia/lymphoma. Diagnosis of lymphoblastic/leukaemia lymphoma was made in 
2015 by morphological and histological study. The patient underwent Moroccan protocol for acute lymphoblastic 
leukaemia (MARALL) from 2015 to 2017 and achieved complete remission. One year later, the patient developed 
an anterior mediastinal mass, relapse was suspected, but the surgical biopsy was performed and histological, the 
mass showed thymoma.  
CONCLUSION: At the time of diagnosis of thymoma for a patient treated for T-lymphoblastic/leukaemia 
lymphoma it is necessary to eliminate a relapse because the distinction between thymoma and T-
lymphoblastic/leukaemia lymphoma is sometimes difficult, and the association is possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Lymphoblastic leukaemia/ lymphoma is a 
neoplasm of lymphoblasts committed to the T-cell 
lineage; it frequently shows mediastinal involvement 
at diagnosis [1] it’s required intensive therapy, with 
chemotherapy, radiation and sometimes stems cell 
transplantation [2]. On the other hand, thymoma is 
thymic epithelial tumours composed of varying 
proportions of neoplastic thymic epithelial cell and 
non-neoplastic thymocyte, with limited malignant 
potential, the treatment consists of surgical resection. 
The distinction between thymoma and lymphoblastic 
leukaemia/ lymphoma can be problematic because of 
the immature lymphocytes associated with thymoma 
may resemble T lymphoblastic leukaemia/lymphoma 
cells both morphologically and immunohistochemically 
[1]. We report a rare case of a patient with secondary 
thymoma which occurred one year after lymphoblastic 
leukaemia/lymphoma and discuss the cause-effect 
relationship and pathogenetic mechanism of thymoma 
and T-cell Lymphoblastic leukaemia/lymphoma and 
present new method on immunohistochemistry to 
distinguish T- Lymphoblastic leukemia /lymphoma 
from thymoma. 
Case Report 
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Case report 
 
A 44-year-old housewife was diagnosed with 
T-lymphoblastic leukaemia/lymphoma on 2015; the 
patient presented four months before her admission 
fever with the anaemic syndrome and chest pain; the 
physical exam normal. There were no palpable lymph 
nodes. 
The white blood cells count found 
normochromic normocytic anaemia with Hb at 10.3 
g/dl, WBC count 12 G/L without peripheral blasts, 
platelet count was at 35 G/L. The chest X-ray and CT 
scan showed pleural infusion with 
mediastinopulmonary mass; the lung biopsy showed 
that the leukemic cells were positive for CD5, CD10, 
CDBcl2, and negative for CD20, CD79a, CD23 and 
TDT. The KI-67 was positive at 90%. Bone marrow 
biopsy showed lymphoblastic cells. Therefore, the 
lymphoma was classified as precursor T cell 
lymphoblastic leukaemia/lymphoma. The karyotype 
was not done. Abdominal ultrasound showed no 
abnormalities. Renal and liver biochemistry profiles 
were essentially normal. 
The patient underwent chemotherapy for 
Lymphoblastic leukaemia/lymphoma according to a 
Moroccan protocol of acute lymphoblastic leukaemia 
which includes one induction, one consolidation, two 
intensifications and maintenance therapy for 2 years. 
Complete remission was achieved; stem cell 
transplantation was not done. One year later, the 
patient complained of chest pain with dyspnoea and 
cough. Computed tomography (CT) scan of the chest 
demonstrated right gangliotumoral process occupying 
almost the entire right lung of heterogeneous density 
containing necrotic zones measuring approximately 
113/123 mm, with secondary pleural and probably 
peritoneal involvement (Figure 1).  
 
Figure 1: CT scan of the chest showing right tumoral process 
 
The white blood cells count was normal. 
Because of the possibility of relapse of her 
Lymphoblastic leukaemia/lymphoma, bone marrow 
aspiration was performed. Lymphoblastic 
leukaemia/lymphoma remains in complete remission. 
Surgical biopsy for the pulmonary mass was 
performed and the immunohistochemical study 
objectives malignant tumour proliferation expressing 
CD3 and Tdt, without expression of CD20, PAX5 and 
CD79a. Cytokeratin AE1/AE2 revealed a contingent of 
epithelial cells; The Ki 67 is of the order of 80%, 
concluding an aspect in favour of a thymoma of type 
B1, the patient was put under protocol C CAP, she 
received 2 cures. 
 
 
Discussion 
 
Thymoma is neoplasm that originates from 
the thymic epithelial cell and is frequently associated 
with mature or immature non-neoplastic lymphocytes 
[1]. This pathology is associated with a variety of 
disorders notably myasthenia gravis (MG) and pure 
red cell aplasia (PRCA) [3]. Thymoma may also be 
associated with Lymphoblastic leukaemia/lymphoma 
on the same lesion [1] or arise before.  
We report the case of thymoma as a 
secondary neoplasm after chemotherapy treatment of 
T Lymphoblastic leukaemia/lymphoma. Considering 
the low survival rate of Lymphoblastic 
leukaemia/lymphoma the risk of second malignancy 
remains underestimated. The incidence of second 
malignancies had been estimated for Lymphoblastic 
leukaemia/lymphoma at 2.1% at 5 years and 4.9% at 
10 years [4]; this incidence is particularly high and 
strongly linked to cranial irradiation [5].  
A study of secondary or concomitant 
neoplasms among adult with Lymphoblastic 
leukaemia/lymphoma was done including 1494 
patients treated for Lymphoblastic 
leukaemia/lymphoma, 23 of them (1.5%) developed 
secondary neoplasms, only one case of secondary 
thymoma was reported [4]. Our report underlines the 
rarity of this association. On the other hand, the risk of 
developing a secondary neoplasm is highest among 
patients who had undergone transplantation as 
postremission therapy [4], it was not the case for our 
patient. 
The difficulty in our case is the exclude 
relapse before retaining the diagnosis of thymoma, 
because of the resemblance both morphologically and 
immunohistochemically between lymphocyte-rich 
thymoma and T-lymphoblastic lymphoma /leukaemia, 
especially with small biopsy. 
Flow cytometric analysis can aid differentiate 
T-lymphoblastic lymphoma/leukaemia from thymoma 
[6], [7]. Immunopositivity of cytokeratin is also 
advisably highlighting a network of epithelial cells in 
thymoma, in contrast to a few potentially entrapped 
residual thymic epithelial cells with Lymphoblastic 
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leukaemia/lymphoma [8].  
The study was done and demonstrated that 
the NOTCH 1 could help to distinguish between 
thymoma and T lymphoblastic lymphoma/leukaemia. 
NOTCH1 is the best-characterised member and was 
discovered from cases of human T-lymphoblastic 
lymphoma/leukaemia harbouring t(7; 9)(q34; q34.4), 
which juxtaposes B enhancer/promoter elements on 
chromosome 7 [9]. NOTCH1 plays a central role in the 
pathogenesis of the T-lymphoblastic 
lymphoma/leukaemia. The NOTCH1 signaling 
pathway is frequently activate in T-lymphoblastic 
lymphoma/leukemia, it’s reported in 50% to 60% of 
patients [10], [11], [12]. In the same study, all 
thymoma tested were negative for NOTCH1, but it 
requires careful interpretation. This IHC marker can 
be helpful for differential diagnosis; unfortunately, this 
test is not available in our laboratory.  
The other specificity of our case is the short 
time between the end of chemotherapy and 
developing thymoma. 
In summary, we report a secondary thymoma 
among adult treated by standard chemotherapy for T-
lymphoblastic lymphoma/leukaemia without stem cell 
transplantation. This case illustrates the rarity of 
thymoma as a secondary neoplasm and insists to the 
distinction between thymoma and relapse of T-
lymphoblastic lymphoma/leukaemia because of the 
very different clinical implications and treatment 
investigations. The use of new marker like NOTCH1 
can be helpful for this distinction.  
 
 
References 
 
1. Ito J, Yoshida A, Maeshima AM, Nakagawa K, Watanabe SI, 
Kobayashi Y, Fukuhara S, Tsuta K. Concurrent thymoma, thymic 
carcinoma, and T lymphoblastic leukemia/lymphoma in an anterior 
mediastinal mass. Pathology-Research and Practice. 2015; 
211(9):693-6. https://doi.org/10.1016/j.prp.2015.06.002 
PMid:26150396  
2. Hoelzer D, Go¨ kbuget N. T-cell lymphoblastic lymphoma and T-
cell acute lymphoblastic leukemia: a separate entity? Clin  
Lymphoma Myeloma. 2009; 9:S214–S221. 
https://doi.org/10.3816/CLM.2009.s.015 PMid:19778844  
3. Chang H, Chen TJ, Chuang WY, Lin TL. Precursor B-cell acute 
lymphoblastic leukemia after thymoma and myasthenia gravis: 
report of a case and review of the literature. Tumori Journal. 2011; 
97(1):126-9. https://doi.org/10.1177/030089161109700123 
PMid:21528677  
 
4. Tavernier E, Le QH, de Botton S, Dhédin N, Bulabois CE, 
Reman O, Vey N, Lhéritier V, Dombret H, Thomas X. Secondary or 
concomitant neoplasms among adults diagnosed with acute 
lymphoblastic leukemia and treated according to the LALA‐87 and 
LALA‐94 trials. Cancer: Interdisciplinary International Journal of the 
American Cancer Society. 2007; 110(12):2747-55. 
https://doi.org/10.1002/cncr.23097 PMid:17963265  
 
5. Walter AW, Hancock ML, Pui CH, et al. Secondary brain tumors 
in children treated for acute lymphoblastic leuke-mia at St Jude 
Children's Research Hospital. J Clin Oncol.1998; 16:3761–3767. 
https://doi.org/10.1200/JCO.1998.16.12.3761 PMid:9850019  
 
6. Li S, Juco J, Mann KP, et al. Flow cytometry in the 
differentialdiagnosis of lymphocyte-rich thymoma from precursor T-
cell acutelymphoblastic leukemia/lymphoblastic lymphoma. Am J 
ClinPathol. 2004; 121:268–274. 
https://doi.org/10.1309/K2FY1TED8GEGFLNG PMid:14983942  
 
7. Gorczyca W, Tugulea S, Liu Z, et al. Flow cytometry in the 
diagnosis of mediastinal tumors with emphasis on differentiating 
thymocytes from precursor T-lymphoblastic lymphoma/leukemia. 
Leuk Lymphoma. 2004; 45:529–538. 
https://doi.org/10.1080/10428190310001598008 PMid:15160915  
 
8. Armin G, Bodo J, Eric D. NOTCH1 Intracellular Domain 
Immunohistochemistry as a Diagnostic Tool to Distinguish T-
Lymphoblastic Lymphoma From Thymoma. Am J Surg Pathol. 
2015; 39:565–572. 
https://doi.org/10.1097/PAS.0000000000000358 PMid:25517959  
 
9. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog 
of the Drosophila notch gene, is broken by chromosomal 
translocations in T lymphoblastic neoplasms. Cell. 1991; 66:649–
661. https://doi.org/10.1016/0092-8674(91)90111-B 
 
10. Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell 
lymphoblastic leukaemia/lymphoma and other haematological 
malignancies. J Pathol. 2011; 223:262–273. 
https://doi.org/10.1002/path.2789 PMid:20967796 
PMCid:PMC2996483 
 
11. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of 
NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 
2004; 306:269–271. https://doi.org/10.1126/science.1102160 
PMid:15472075  
 
12. Gallo Llorente L, Luther H, Schneppenheim R, et al. 
Identification of novel NOTCH1 mutations: increasing our 
knowledge of the NOTCH signaling pathway. Pediatr Blood 
Cancer. 2014; 61: 788–796. https://doi.org/10.1002/pbc.24852 
PMid:24249312  
 
 
